循环肿瘤 DNA 在 KRAS 阳性结直肠癌患者中的预后价值：一项系统综述和荟萃分析。
Circulating Tumor DNA in KRAS positive colorectal cancer patients as a prognostic factor - a systematic review and meta-analysis.
机构信息
Student Scientific Circle of Department of General, Endocrine and Transplant Surgery, Medical University of Gdansk, Gdansk, Poland.
Department of General, Endocrine and Transplant Surgery, Medical University of Gdansk, Gdansk, Poland.
出版信息
Crit Rev Oncol Hematol. 2020 Oct;154:103065. doi: 10.1016/j.critrevonc.2020.103065. Epub 2020 Aug 1.
BACKGROUND
Liquid biopsy is a novel tool in oncology. It provides minimally invasive detection of tumor specific DNA. This review summarizes data on presence of circulating tumor DNA in serum or plasma of CRC patients as a potential negative prognostic factor.
MATERIALS AND METHODS
The systematic review was performed according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses). The search was performed using PubMed, Web of Science and Scopus.
RESULTS
In total 18 articles with a total of 1779 patients met the inclusion criteria. Six out of 8 studies found that presence of ctDNA in plasma/serum was associated with inferior overall survival. All 6 studies found that high concentrations of ctDNA in plasma/serum was associated with inferior overall survival.
CONCLUSIONS
Presence or high concentrations of KRAS mutation in plasma or serum were associated with inferior prognosis. Establishing cut-off concentrations is warranted for further clinical implementation of liquid biopsy.
背景
液体活检是肿瘤学中的一种新工具。它提供了对肿瘤特异性 DNA 的微创检测。这篇综述总结了 CRC 患者血清或血浆中循环肿瘤 DNA 作为潜在负预后因素的存在的数据。
材料和方法
系统评价按照 PRISMA（系统评价和荟萃分析的首选报告项目）进行。使用 PubMed、Web of Science 和 Scopus 进行了搜索。
结果
总共 18 篇文章，共 1779 名患者符合纳入标准。8 项研究中有 6 项发现血浆/血清中存在 ctDNA 与总体生存率降低相关。所有 6 项研究均发现血浆/血清中 ctDNA 浓度高与总体生存率降低相关。
结论
血浆或血清中 KRAS 突变的存在或高浓度与预后不良相关。有必要确定临界浓度值，以进一步将液体活检临床应用。
Zotero 插件